Cargando…

Features and Management of Late Relapse of Nonseminomatous Germ Cell Tumour

BACKGROUND: Late relapse (LR) of nonseminomatous germ cell tumour (NSGCT) is uncommon, with limited data published. LR is defined as relapse occurring after a disease-free interval of 2 yr. OBJECTIVE: To review features of NSGCT LR in a UK tertiary centre. DESIGN, SETTING, AND PARTICIPANTS: A total...

Descripción completa

Detalles Bibliográficos
Autores principales: Jay, Alexander P.M., Aldiwani, Mohammed, O’Callaghan, Michael E., Pearce, Adam K., Huddart, Robert A., Mayer, Erik, Reid, Alison H., Nicol, David L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317789/
https://www.ncbi.nlm.nih.gov/pubmed/34337537
http://dx.doi.org/10.1016/j.euros.2021.04.008
_version_ 1783730121280061440
author Jay, Alexander P.M.
Aldiwani, Mohammed
O’Callaghan, Michael E.
Pearce, Adam K.
Huddart, Robert A.
Mayer, Erik
Reid, Alison H.
Nicol, David L.
author_facet Jay, Alexander P.M.
Aldiwani, Mohammed
O’Callaghan, Michael E.
Pearce, Adam K.
Huddart, Robert A.
Mayer, Erik
Reid, Alison H.
Nicol, David L.
author_sort Jay, Alexander P.M.
collection PubMed
description BACKGROUND: Late relapse (LR) of nonseminomatous germ cell tumour (NSGCT) is uncommon, with limited data published. LR is defined as relapse occurring after a disease-free interval of 2 yr. OBJECTIVE: To review features of NSGCT LR in a UK tertiary centre. DESIGN, SETTING, AND PARTICIPANTS: A total of 3064 patients were referred from January 2005 to December 2017. We identified patients who experienced LR after initial pathology demonstrated NSGCT and reviewed data for their original and LR presentation and management. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Outcomes included time to LR measured from the date of diagnosis, and overall survival.  This was assessed using  Cox proportional Hazards modelling, with stratification or adjustment for potential confounders. RESULTS AND LIMITATIONS: We identified 101 patients with LR; the median time to LR was 96 mo. Forty-three patients (42.6%) experienced relapse after 10 yr. Univariable log-rank testing revealed that the median time to LR was significantly shorter for patients who had not received induction chemotherapy (iCTx; 54 mo, 95% confidence interval [CI] 48–108) than for those who did (112 mo, 95% CI 84–186; p = 0.04). Patients who had received iCTx were less likely to have elevated tumour markers (36% vs 46%) and more likely to undergo initial surgical resection at LR compared to CTx-naïve patients. Postpubertal teratoma (PPT), yolk sac, and dedifferentiated elements predominated for patients with iCTx exposure, whereas active GCT or fibrosis predominated in postchemotherapy resections for CTx-naïve patients at LR. Forty-one men underwent postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) as part of their initial treatment for metastatic disease. Of these, 20 experienced LR in the retroperitoneum, with 18 undergoing repeat RPLND as part of their LR management. Fifteen of the repeat RPLND histopathology specimens had a PPT component. There have been 23 deaths overall; survival was worse for patients presenting with symptoms (13/36, 33%) and those receiving CTx and no surgery (10/17, 59%) at LR. CONCLUSIONS: When LR of NSGCT occurs, it is frequently after an extended interval and is later among patients with prior iCTx, with PPT predominating. The high frequency of LR within the retroperitoneum following PC-RPLND reinforces the need for good-quality PC-RPLND. PATIENT SUMMARY: We reviewed data for patients who had a late relapse of testicular cancer. We found that patients who did not receive chemotherapy as the first treatment for their initial diagnosis had a shorter time to relapse. Our results highlight the importance of long-term follow-up for testicular cancer.
format Online
Article
Text
id pubmed-8317789
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83177892021-07-29 Features and Management of Late Relapse of Nonseminomatous Germ Cell Tumour Jay, Alexander P.M. Aldiwani, Mohammed O’Callaghan, Michael E. Pearce, Adam K. Huddart, Robert A. Mayer, Erik Reid, Alison H. Nicol, David L. Eur Urol Open Sci Testis Cancer BACKGROUND: Late relapse (LR) of nonseminomatous germ cell tumour (NSGCT) is uncommon, with limited data published. LR is defined as relapse occurring after a disease-free interval of 2 yr. OBJECTIVE: To review features of NSGCT LR in a UK tertiary centre. DESIGN, SETTING, AND PARTICIPANTS: A total of 3064 patients were referred from January 2005 to December 2017. We identified patients who experienced LR after initial pathology demonstrated NSGCT and reviewed data for their original and LR presentation and management. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Outcomes included time to LR measured from the date of diagnosis, and overall survival.  This was assessed using  Cox proportional Hazards modelling, with stratification or adjustment for potential confounders. RESULTS AND LIMITATIONS: We identified 101 patients with LR; the median time to LR was 96 mo. Forty-three patients (42.6%) experienced relapse after 10 yr. Univariable log-rank testing revealed that the median time to LR was significantly shorter for patients who had not received induction chemotherapy (iCTx; 54 mo, 95% confidence interval [CI] 48–108) than for those who did (112 mo, 95% CI 84–186; p = 0.04). Patients who had received iCTx were less likely to have elevated tumour markers (36% vs 46%) and more likely to undergo initial surgical resection at LR compared to CTx-naïve patients. Postpubertal teratoma (PPT), yolk sac, and dedifferentiated elements predominated for patients with iCTx exposure, whereas active GCT or fibrosis predominated in postchemotherapy resections for CTx-naïve patients at LR. Forty-one men underwent postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) as part of their initial treatment for metastatic disease. Of these, 20 experienced LR in the retroperitoneum, with 18 undergoing repeat RPLND as part of their LR management. Fifteen of the repeat RPLND histopathology specimens had a PPT component. There have been 23 deaths overall; survival was worse for patients presenting with symptoms (13/36, 33%) and those receiving CTx and no surgery (10/17, 59%) at LR. CONCLUSIONS: When LR of NSGCT occurs, it is frequently after an extended interval and is later among patients with prior iCTx, with PPT predominating. The high frequency of LR within the retroperitoneum following PC-RPLND reinforces the need for good-quality PC-RPLND. PATIENT SUMMARY: We reviewed data for patients who had a late relapse of testicular cancer. We found that patients who did not receive chemotherapy as the first treatment for their initial diagnosis had a shorter time to relapse. Our results highlight the importance of long-term follow-up for testicular cancer. Elsevier 2021-06-07 /pmc/articles/PMC8317789/ /pubmed/34337537 http://dx.doi.org/10.1016/j.euros.2021.04.008 Text en Crown Copyright © 2021 Published by Elsevier B.V. on behalf of European Association of Urology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Testis Cancer
Jay, Alexander P.M.
Aldiwani, Mohammed
O’Callaghan, Michael E.
Pearce, Adam K.
Huddart, Robert A.
Mayer, Erik
Reid, Alison H.
Nicol, David L.
Features and Management of Late Relapse of Nonseminomatous Germ Cell Tumour
title Features and Management of Late Relapse of Nonseminomatous Germ Cell Tumour
title_full Features and Management of Late Relapse of Nonseminomatous Germ Cell Tumour
title_fullStr Features and Management of Late Relapse of Nonseminomatous Germ Cell Tumour
title_full_unstemmed Features and Management of Late Relapse of Nonseminomatous Germ Cell Tumour
title_short Features and Management of Late Relapse of Nonseminomatous Germ Cell Tumour
title_sort features and management of late relapse of nonseminomatous germ cell tumour
topic Testis Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317789/
https://www.ncbi.nlm.nih.gov/pubmed/34337537
http://dx.doi.org/10.1016/j.euros.2021.04.008
work_keys_str_mv AT jayalexanderpm featuresandmanagementoflaterelapseofnonseminomatousgermcelltumour
AT aldiwanimohammed featuresandmanagementoflaterelapseofnonseminomatousgermcelltumour
AT ocallaghanmichaele featuresandmanagementoflaterelapseofnonseminomatousgermcelltumour
AT pearceadamk featuresandmanagementoflaterelapseofnonseminomatousgermcelltumour
AT huddartroberta featuresandmanagementoflaterelapseofnonseminomatousgermcelltumour
AT mayererik featuresandmanagementoflaterelapseofnonseminomatousgermcelltumour
AT reidalisonh featuresandmanagementoflaterelapseofnonseminomatousgermcelltumour
AT nicoldavidl featuresandmanagementoflaterelapseofnonseminomatousgermcelltumour